Factor V and factor Vlll are homologous cofactors in the blood coagulation cascade that have the domain structure Al-A2-B-A3-Cl-C2, of which the B domain has extensively diverged. In transfected COS-l monkey cells, expression of factor Vlll is approximately 10-fold less efficient than that of factor V, primarily because of inefficient protein secretion and, t o a lesser extent, reduced mRNA expression. To study the functional significance and effect of the B domain on expression and activity, chimeric cDNAs were constructed in which the B domains of factor V and factor Vlll were exchanged. Expression of a factor Vlll chimera harboring the B-domain of factor V yielded a fully functional factor Vlll molecule that was expressed twofold more efficiently than wild-type factor Vlll because of increased mRNA expression. Thus, sequences within the factor Vlll B domain were not responsible for the inefficient secretion of factor Vlll compared with factor V. Expression of a factor V chimera harbor-LOOD COAGULATION is controlled by the regulated activation of serine proteases in the coagulation cascade. Factor VI11 and factor V are two large glycoproteins that function as essential cofactors for proteolytic activation of factor X and prothrombin, respectively. Both proteins circulate in plasma as inactive precursors that are activated through limited proteolysis by either thrombin or activated factor X (Xa). After activation, factor VIIIa and factor Va assemble with their respective substrates (factor X and prothrombin) and enzymes (factor IXa and factor Xa) on a negatively charged phospholipid surface in the presence of calcium ions.',2 Both cofactors act to increase the Vmax of substrate activation by four orders of magnitude. Elucidation of the primary structure of factors V',4 and VII15.6 showed that they share amino acid identity and have a conserved domain organization of Al-A2-B-A3-Cl-C2 (Fig l) . The A domains are homologous to the A domains of ceruloplasa copper-binding plasma protein, suggesting a role in metal-ion binding. The C domains are homologous to phospholipid-binding proteins, suggesting a role in phospholipid interaction.x Whereas the A and C domains are 40% identical between factors V and VIII, there is only limited homology between the B domains.' However, both B domains do contain a large number of asparagine-linked oligosaccharides. Within the genome, the factor VI11 and factor V B domains reside on unusually large single exons,'".'' ing the B domain of factor Vlll was slightly reduced compared with wild-type factor V, although the secreted molecule had significantly reduced procoagulant activity correlating with dissociated heavy and light chains and resistance to thrombin activation. Interestingly, the factor V chimera containing the factor Vlll B domain was efficiently activated by Russell's viper venum (RW). Afactor V B domain deletion (residues 710-1545) molecule also exhibited significantly reduced procoagulant activity caused by resistance t o thrombin cleavage and activation, although this molecule was activatable by R W . These results show that, in contrast t o factor VIII, thrombin activation of factor V requires sequences within the B domain. In addition, thrombin activation of factor V occurs through a different mechanism than activation by RVV. 0 1994 b y The American Society of Hematology.
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suggesting that the B domains evolved from a single exon and may function in similar roles in regulating the expression and activity of factors V and VIII.
In plasma, factor VI11 circulates as a metal-ion bridged heterodimer consisting of a heavy chain of 200 kD and a light chain of 80 kD that are processed from a single-chain precursor polypeptide within the B domain on secretion from the This heterodimer is stabilized by interaction with another plasma glycoprotein, von Willebrand factor." In contrast, plasma factor V is a single-chain polypeptide of 330 kD and is not detected in association with other plasma proteins.l4.ls Both factor V',""' and factor VIII'9-2' require proteolytic activation to elicit full procoagulant activity. Thrombin activation of factor VI11 results in cleavage initially after residue 740 and subsequently after residues 372 and 1689 (Fig 1) . Thrombin-activated factor VI11 consists of a heterotrimer of a 50-kD AI-domain-derived polypeptide, a 43-kD A2-domain-derived polypeptide, and a 73-kD-derived light-chain Thrombin cleavage of factor V occurs first after residue 709 and then after residues 1018 and 1545 to yield the activated heterodimer consisting of the 94-kD (also referred to as a 105-kD polypeptide)25 heavy-chain fragment and the 74-kD light-chain Upon thrombin activation, the B domains of both factors V and VIII are released.
Previous studies showed that the B domain of factor VI11 is dispensible for procoagulant activity.**-'" Factor VI11 Bdomain deletion molecules extending from residue 740 to 1689 exhibit specific activity similar to wild-type factor VIII and are expressed more efficiently because of a more efficient One B-domain deletion molecule, LA-VIII, was active in vivo, as measured by its ability to correct the cuticle bleeding time on infusion into a hemophilic dog." However, detailed characterization indicated that different B-domain deletion mutants have altered patterns of thrombin activation, possibly caused by an altered context of the thrombin cleavage Similarly, deletion of residues 81 1-1491 within the B domain did not destroy factor V activity in vitro." In the studies described here, we evaluated the influence of the B domain on expression and functional Thrombin (Ha) cleaves the heavy chain at residues 740 and 372 to generate the 43-kD and 50-kD polypeptides and after 1689 to generate the 73-kD light chain (C). Factor V is secreted as a single-chain polypeptide (D) and is cleaved by thrombin at arginine residues 709,1018, and l545 to generate the heterodimer composed of the 94-kD heavy chain and 74-kD light chain. Wild-type factor Vlll (VIII), the factor Vlll B-domain deletion (LA-VIII), the factor Vlll hybrid harboring the B-domain of factor V (VlllB5). wildtype factor V (V), the factor V hybrid harboring the factor Vlll Bdornain (VB8), and the factor V B-domain deletion ( V The results show a unique requirement of the factor V B domain for activity and thrombin activation.
MATERIALS AND METHODS

Materials.
Rabbit anti-factor V polyclonal antibody was purchased from Dako Corp (Carpinteria, CA). Anti-factor VIII heavy chain monoclonal antibody (MoAb) F-8 was previously described?' Anti-factor VI11 light chain MoAb was obtained from Hybritech Corp (La Jolla, CA). Factor V MoAb E9 directed against the factor V light chain'* was kindly provided by D r K.G. Mann (University of Vermont, Burlington, VT). Factor VIII-deficient plasma, factor V-deficient plasma, and normal pooled human plasma were obtained from George B. King Biomedical Inc (Overland Park, KS). Thromboplastin, soybean trypsin inhibitor, phenylmethylsulfonyl floride, and aprotinin were purchased from Sigma Corp (St Louis, MO). Human thrombin, human factor Xa, human factor V, and Russell's viper venom (RVV) were obtained from Hematological Technology Isolation of a genomic clone encoding the factor V B domain.
Previously reported human factor V cDNA sequence^'.^ differed in the number of a 9 amino acid repeat within the B domain. We therefore characterized whether the cDNA previously isolated4 was representative of that encoded by the human genome. The factor V B domain was isolated from a human genomic DNA library constructed in the Lambda Fix replacement vector (Stratagene, La Jolla, CA) by hybridization to an [(u-~'P]-~ATP and [(Y-~'P]-~CTP nicktranslated 2.5-kb Pst I-Kpn I fragment from the factor V cDNA encoding the entire B d~main.'~ The genomic B domain fragment from phage 6 was isolated as an approximately 2-kb Sac I fragment and subcloned for sequencing. DNA sequences were determined on both strands using the collapsed-supercoil dideoxy chain termination methodgs with Bluescript primers and factor V-specific synthetic oligonucleotides. The DNA sequence of the entire B domain, spanning from the 5' to the 3' introdexon boundary, was identical to the previously identified cDNA sequence? The deduced amino acid
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From sequence differed at 4 amino acid residues from the human genomic sequence previously published." The sequence of the B-domain confirmed the presence of 37 repeats of 9 amino acids and ruled out the presence of additional repeats within the factor V gene that were deleted through cDNA cloning.
Derivation of the factor V expression vector. The full-length factor V cDNA was assembled from two overlapping Charon 21A recombinants each containing portions of the factor V cDNA derived from an oligo-dT-primed human fetal liver library.4 The recombinants designated V401 and V1 were digested with Sac 11 to remove the factor V cDNA and flanking lambda sequences and ligated to Sac It-linearized Bluescript KS+ cloning vector (Stratagene). The resulting plasmids were designated 401B5-6 and VlBS-IO, respectively. The lambda sequences were removed from 410B5-6 by digestion with Hha I (nucleotide 41 in the factor V CDNA)? followed by treatment with the Klenow fragment of DNA polymerase I. The plasmid DNA was then digested with Bgl I1 (nucleotide 4275 in the factor V cDNA) and the 4234 fragment was cloned into the EcoRV and BamHI cloning sites of Bluescript KS+, generating plasmid Blu 401. The Sal I site derived from the Bluescript polylinker provides a unique cloning site 5' to the initiator methionine codon.
VlBS-10 was digested with Hpa I (nucleotide 6854 in the factor V cDNA4) removing flanking lambda sequence and 71 bp of the 3' noncoding sequence. An EcoRI adapter (5'-AATTCCGTCGAC-TCTAGAG-3') containing a Sal 1 site was ligated to the Hpa Idigested VlBV-10 resulting in the plasmid BluVI-RI. The unique BstEII site (nucleotide 3666 in the factor V cDNA) present in both clones was used to assemble the full-length factor V cDNA. The 3625 Sal I-BstEII fragment from Blu401 contributing the 5' end of the factor V cDNA and the 3188 Sal I-BstEII fragment from BluV 1-RI contributing the 3' end of the cDNA were ligated to Sal Ilinearized Bluescript KS, resulting in the plasmid containing the full-length factor V cDNA (Bluescript-V).
A Sal I derivative of the expression vector pMT2 was constructed by cloning an adapter (5'-AATTCCGTCGAACTCTAGAG-3') into the EcoRI site. The full-length factor V cDNA was excised from Bluescript-V on a Sal I fragment and cloned into the Sal I-containing derivative of the expression vector pMT2" and was designated pMT2-V. Plasmid mutagenesis and hybrid construction. The factor VI11 expression vector pMT2-VI11 was previously de~cribed.'~ Both Bluescript-V and pMT2V were used for construction of hybrid molecules. Site-directed oligonucleotide-mediated mutagenesis was performed by the heteroduplex procedure" to sequentially introduce unique Mlu I restriction sites at proteolytic cleavage sites at residues 740 and 1648 within factor VI11 (designated pMT2-VI11 Mlu 1-740 and pMT2-VI11 Mlu l-1648) and at residues 709 and 1545 within factor V (designated pMT2-V Mlu 1-709 and Bluescript-V Mlu 1-1545). The Mlu I sites facilitate exchange of the B-domain segments. The oligonucleotides used for mutagenesis were the following (residue and mutagenic oligonucleotide): factor VIII: 740, 5'-GTAAAAACAATGCCATTGAAACGCGTAGCTTCTCCCAGAAlTC-3', 1648, 5"CCAGTCTT GAAACGCCATACGCGTGAAATAACTCGTACTACTC-3'; factor V: 709,5'-GGCTGCAGCATTAGGAACGCGTTCATTCCG-GCGTAGCAACAATGGAAACAGAAG-3'. All mutations were confirmed by DNA sequencing and extensive mapping with restriction enzymes.
The factor V chimera harboring the B-domain of factor VIII, designated pVB8, was constructed by a 4-way ligation of the Mlu I and BspMI fragment from pMT2-V Mlu 1-709, the Mlu I and BspMI fragment from Bluescript-V Mtu 1-1545, the Mlu I-EcoRV fragment from pMT2-VIII Mlu 1-1648, and the Mlu I-EcoRV fragment from pMT2-VI11 Mlu 1-740. The factor VI11 hybrid containing the B domain of factor V, designated pVIIIB5, was generated by a DNA transfection and analysis. Plasmid DNA was transfected into COS-l cells by the diethylaminoethyl (DEAE)-dextran procedure." Conditioned medium was harvested 60 hours posttransfection in the presence of 10% heat-inactivated fetal bovine serum for factor V and factor VI11 assay. Primary translation products were analyzed by pulse-labeling cells for 15 or 30 minutes, as indicated, with [3'S]-methionine (250 pCi/mL in methionine-free medium) and preparing cell extracts in a Nonidet-P40 lysis buffer.'* Protein secretion was monitored by metabolically labeling cells with ["SI-methionine (250 pCilmL for 2 hours) and chase performed for 4 hours in medium containing excess unlabeled methionine as described." The factor VI11 was immunoprecipitated with an anti-factor VI11 MoAb F-8'' coupled to CL-4B sepharose. Quantitatively similar results were obtained with an anti-factor VI11 light chain MoAb (data not shown). Factor V was immunoprecipitated with either MoAb E-9 specific to the factor V light chain'' or a rabbit polyclonal antibody coupled to Affigel (BioRad, Richmond, CA). The antibodies were tested before the experiments to determine the amount of antibody required for quantitative immunoprecipitation. In all cases, excess antibody was used. The immunoprecipitates were washed as described.'" Immunoprecipitated proteins from the conditioned medium were resuspended 50 mmoVL Tris-HCI, pH 7.5, 150 mmol/L NaCI, 2.5 mmol/L CaC12, and 5% glycerol (buffer A) and subjected to digestion with thrombin ( I2 U/mL for 60 minutes at 37°C) before electrophoresis on a sodium dodecyl sulfate (SDS)-low bis-8% polyacrylamide gel." Proteins were visualized by autoradiography after fluorography by treatment with En'Hance (Dupont, Boston, MA). The band intensities were quantitated by scanning the lanes using an LKB UltroScan XL laser densitometer (Pharmacia LKB Biotechnology Inc, Uppsala, Sweden).
Total RNA was isolated from transfected COS-l cells at 60 hours posttransfection using the guanidine thiocyanate method.'" RNA was fractionated on a 0.8% agarose formaldehyde gel and subsequently transferred to nitrocellulose."' Probes were prepared by nick translation of dihydrofolate reductase (DHFR) or chicken P-actin cDNA fragments." Transcripts were analyzed by hybridization at 65°C in a solution containing 2X SSC, 0.1% SDS, 5 X Denhart's reagent, and 100 pg/mL denatured salmon sperm DNA, followed by autoradiography and densitometric scanning.
Factor VI11 and factor V activity assay. Factor VI11 activity was measured by a chromogenic assay5 or in a clotting assay using factor VIII-deficient plasma.24 One unit of factor VI11 activity is that amount measured in 1 mL of normal human pooled plasma. For thrombin activation, conditioned medium was diluted into buffer A and incubated at room temperature with 1 UlmL thrombin. At short intervals, the sample was diluted and assayed for factor VI11 activity in a factor VI11 clotting assay.
Factor V activity was measured in a factor V clotting assay using factor V-deficient pla~ma.~' Standard curves were prepared by dilution of pooled normal plasma in 20 mmol/L imidazole, pH 7.4, and 0.15 mol/L NaCl (buffer B). Total factor V was determined by measuring the peak activity after treatment with thrombin. Factor V conditioned medium was incubated at room temperature with 1 U/ mL thrombin. At timed intervals, aliquots were removed and assayed. The activation quotient was determined by dividing the thrombin-activated activity by the nonactivated activity. One unit of factor V is that amount in 1 mL of normal pooled human plasma before activation with thrombin. Factor Xa activation was performed PV,,,, .
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RVV activation was performed at 2 p.g/mL RVV in 20 mmol/L imidazole. pH 7.4. 0.15 mol/L NaCI, and 20 mmol/L CaCI2. Before assay the samples were diluted into 20 mmol/L imidazole, pH 7.4, 0.15 mol/L NaCl and 2 mmol/L EGTA. Optimal RVV activity required the addition of 20 mmol/L CaCI2. The reactions were diluted into 2 mmol/L EGTA to reduce the calcium ion concentration to prevent calcium activation in the clotting assay.
Ann/wis of fl~rotnbin nc/ivnfion and clrnvnge. At 60 hours posttransfection, cells were metabolically labeled with ["SI-methionine (250 pCilmL) as described above and conditioned medium was harvested." Factor V was immunoprecipitated with an anti-factor V polyclonal antibody. The immunoprecipitates were resuspended in buffer A, aliquoted, and treated with increasing concentrations of thrombin at 37°C for I hour. Factor VI11 was immunoprecipitated with the MoAb F8 coupled to CL4B sepharose. The immunoprecipitated protein was resuspended in buffer A and treated with 1.5 U/ mL thrombin at room temperature for the indicated periods of time. Reactions were terminated by the addition of 2-mercaptoethanol (2.5%) and SDS (0.5%) and heating at 85°C. The resulting polypeptides were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized after fluorography by treatment with En'Hance.
RESULTS
Factor Vlll, compared with factor V, is ineflciently secreted from COS-] monkey cells. Factor V and factor VI11 mRNA and protein expression were compared by transient transfection in COS-l monkey cells. The factor V and factor VI11 cDNA expression vectors were transfected into COS-l cells and, after 60 hours, factor V and factor VI11 mRNA expression was measured by Northern blot analysis of total RNA. Because DHFR sequences are present in the 3' end of the mRNAs derived from the expression vector pMT2, hybridization to a single "P-labeled DHFR probe permits comparison of mRNA levels from vectors having different cDNA inserts. The results showed that the level of factor V rnRNA was approximately twofold greater than factor VI11 (Fig 2, lanes 2 and 3, and Table l) . Factor V and factor VI11 protein synthesis were evaluated by immunoprecipitation of cell extracts prepared from ['5S]-methionine pulse-labeled cells. Analysis of extracts from cells transfected with pMT2-V detected a prominent polypeptide migrating at 330 kD (Fig 2, lane 5) that was not present in cells that did not receive DNA (Fig 2, lane 4) . Similar analysis of extracts from pulse-labeled cells transfected with pMT2-VI11 detected a single-chain polypeptide of 280 kD on irnmunoprecipitation with anti-factor VI11 antibody (Fig 2, lane 6) . Comparison of the primary translation products for factor VI11 and factor V showed that factor V synthesis was approximately twofold greater than factor VI11 (Fig 2, lanes 5 and  6) . The factor V and factor VI11 primary translation products contain 52 and 60 methionine residues, respectively. Thus, the difference in translation rates was proportional to the different mRNA levels.
The secreted factor V and factor VI11 were analyzed by immunoprecipitation of conditioned medium after a 4-hour chase period in medium containing excess unlabeled methionine. Factor V was recovered in the conditioned medium as an abundant polypeptide migrating at 330 kD (Fig 2, lane  9 ). Thrombin digestion of the immunoprecipitated protein before electrophoresis yielded the expected cleavage products representing the 150-, 94-, and 74-kD fragments (Fig  2, lane IO) that are characteristic of plasma-derived factor V.'5 In contrast, low amounts of factor VI11 were detected in the conditioned medium that migrated as a 200-kD heavy chain and a 80-kD light chain (Fig 2, lane 1 l) . Thrombin digestion of the immunoprecipitated factor VI11 yielded the expected cleavage products migrating at 73, 50, and 43 kD (Fig 2, lane 12) .2'.37 In this analysis, the 73-kD polypeptide migrates just below the 69-kD marker. Quantitation of data averaged from six independent transfection experiments showed that the amount of radiolabeled factor V polypeptide secreted into the conditioned medium was IO-fold greater than observed for factor VI11 ( Table I) . These results show that factor V was more efficiently expressed than factor VI11 in COS-l cells. The increased factor V expression resulted * COS-l cells were transfected with pMT2-V or pMT2-VIII and at 60 hours posttransfection expression was analyzed as described in Materials and Methods. Total RNA was isolated and Northern blot analysis performed by hybridization to a DHFR probe. Band intensities were quantitated and the ratio of factor V mRNA to factor Vlll mRNA is shown with the standard deviation (SD) for four independent transfection experiments. In parallel, cells were pulse-labeled with [%]-methionine for 15 minutes and cell extracts were prepared for immunoprecipitation and SDS-PAGE analysis. The band intensities for the primary translation products were determined for three independent experiments and the ratio of factor V to factor Vlll is shown. Protein secreted into the conditioned medium was quantitated by [35Sl-methionine pulse-labeling with a 4-hour chase in medium containing excess unlabeled methionine. Protein was immunoprecipitated and digested with thrombin before SDS-PAGE. For more consistent quantitation of the secreted protein, the band intensities of the thrombin cleaved light chain for factor V and factor Vlll were scanned by a densitometer. The factor V and factor Vlll light chains contain 20 and 19 methionine residues, respectively. The ratio of secreted factor V to factor Vlll protein is presented from six independent transfection experiments.
t Factor VIll secreted protein and the mRNA levels were quantitated from the data in Figs 3 and 4 as described above. Quantitation of primay translation products was from data not shown and activity was from data shown in Table 2. * Factor V secreted protein and the mRNA levels were quantitated from the data in Figs 3 and 4 as described above, except that the quantitation of secreted protein was performed before thrombin digestion by adding the band intensities for all radiolabeled factor Vrelated polypeptides in the conditioned medium. All values presented are from the same transfection experiment and are relative to the values obtained for wild-type factor Vlll and factor V. Independent transfection experiments yielded data consistent with those presented for factor Vlll and factor V. The activity values presented are results from factor V and factor Vlll clotting assays as described in Materials and Methods.
from an approximately twofold increase in mRNA level and a fivefold increase in secretion efficiency.
B-domain sequences do not inhibit secretion of factor VIII. Because the B domains of factors V and VI11 are evolutionarily the least conserved domains of the molecule, we asked whether the B-domain sequences contribute to the 10-fold difference in expression. To characterize sequences within factor VI11 and factor V that were responsible for differences in mRNA expression and/or secretion, B-domain deletions as well as chimeric cDNAs with exchanged B domains were constructed (depicted in Fig  I , bottom) . The boundaries of the B-domain chimeras were chosen to coincide with known proteolytic cleavage sites. To facilitate construction of the hybrid cDNAs, first unique MZu I restriction sites, that encode Thr-Arg, were introduced into the cDNAs of both factor VI11 (residue 739-740) and factor V (residue 708
Chimeric cDNAs were then constructed by exchanging the B domain encoding MZu I fragments between the factor V and factor VI11 expression plasmids. A factor V cDNA was constructed in which the factor VI11 B domain (residues 740 to 1648) replaced the factor V B domain (residues 709 to 1545) and was designated VB8. A factor VI11 cDNA was constructed in which the factor V B domain (residues 709 to 1545) replaced the factor VI11 B domain (residues 740 to 1648) and was designated VIIIB5. In addition, a factor V B-domain deletion molecule was also constructed and designated VY4,74r as described in Materials and Methods. The factor VI11 B-domain deletion molecule designated LA-VI11 with residues 759 to 1639 deleted was previously characterPlasmid DNA expression vectors harboring wild-type, Bdomain deletion mutants of factors V and VI11 and chimeric cDNAs were transfected into COS-l cells. The synthesis and processing of these molecules was studied by metabolically labeling cells with [?3]-methionine and immunoprecipitation of the conditioned medium with either an anti-Factor VI11 heavy chain or an anti-factor V light chain antibody and reducing SDS-PAGE. Compared with secretion of wildtype factor VI11 (Fig 3, lane I) , secretion of wild-type factor V was increased sixfold (Fig  3. lane 7) . Secretion of the factor VI11 deletion molecule LA-VI11 was increased 1.3-fold compared with wild-type factor VI11 (Fig 3, lane 3) . Expression of the VIIIB5 chimera was twofold greater than wild-type factor VI11 (Fig 3, lane 3) . The chimeric protein VIIIB5 was secreted as a single-chain polypeptide of the expected size 330 kD. Thrombin digestion of the immunoprecipitated VIIIB5 protein generated the 73-kD light-chain fragment and the 50-kD and 43-kD heavy-chain fragments that comigrated with those derived from thrombin digestion of wild-type factor VI11 and LA-VI11 (Fig 3, lanes 2 . 4, and 6) and a fragment migrating below the 200-kD marker, likely representing the factor V B domain.
In contrast to wild-type factor V (Fig 3, lane 7) , immunoprecipitation analysis of the VB8 chimera using factor V light-chain-specific antibody detected an approximately 3 10-kD polypeptide, likely representing single-chain VB8. and the cleaved light chain, migrating at 74 kD (Fig 3, 9). Secretion of the single-chain V98 chimera (Fig 3, lane  9) was slightly reduced compared with wild-type factor V (Fig 3, lane 7) . However. secretion of the B-domain deletion molecule (Fig 3, lane I I ) was increased 2.3-fold compared with wild-type factor V. Upon thrombin digestion of VB8, the single-chain polypeptide was cleaved to lower molecular weight fragments, including one that comigrated approximately with the 94-kD factor V heavy chain (Fig 3, lanes  8 and IO) . In contrast, the majority of the secreted Vgdn4 B-domain deletion molecule was resistant to thrombin cleavage (Fig 3, lane 12) . In addition to analysis by immunoprecipitation of the conditioned media described above, factor VI11 and factor V wild-type and mutant proteins were detected in the total conditioned medium on SDS-PAGE analysis. This analysis yielded quantitatively similar results to those obtained on immunoprecipitation (data not shown). This finding indicated that the differences in expression were not caused by differences in antibody reactivity.
Replacement ?f factor V B-domain sequences into factor VI11 increases mRNA expression. The above results and other data not shown demonstrated a reproducible increase in expression of the VIIIBS chimera compared with wildtype factor VIII. In addition, the expression of B-domaindeleted factor V was also increased, whereas expression of V98 was slightly reduced compared with wild-type factor V. To determine if the differences in expression were caused by mRNA levels, translation, or secretion efficiencies, RNA was prepared from transfected cells and analyzed by Northem blot analysis using a DHFR probe to permit comparison of mRNA levels for the different expression vectors. The factor V mRNA was expressed at a fivefold greater level than the factor VI11 mRNA in this experiment (Fig 4A, compare lanes 2 and 7) . The VB8 and VIIIBS chimeric molecules yielded mRNA levels that were intermediate between the levels for wild-type factor V and wild-type factor VI11 (Fig 4A, lanes 4 and S). Deletion of the B domain of either factor VI11 or factor V increased the mRNA level significantly, ie, 17-and 3.4-fold, respectively (Fig 4, lanes 3 and 6, and Table l ) . Hybridization to a @-actin probe showed that the RNA was loaded equivalently in all lanes (Fig 4B) . Independent transfection experiments gave results that were consistent with those presented in Figs 3 and 4. Analysis of extracts from ["SI-methionine pulse-labeled cells showed that the level of the primary translation products were proportional to the mRNA levels for all wild-type and mutant molecules (data not shown, summarized in Table l ) . Whereas deletion of the B domain in factor V increased mRNA and secreted protein, deletion of the factor VIII B domain (LA-VIII) increased mRNA level 17-fold, but only yielded a 1.3-fold increase in secreted protein. These results show that the levels of secreted protein for the B-domain chimeras and the B-domain-deleted factor V94nA were proportional to the levels of their mRNAs. In contrast, although B-domain-deleted factor VI11 yielded a significant increase in mRNA and primary translation product compared with wild-type factor VIII, there was little increase in the amount of protein secreted into the conditioned medium ( Table l ) . Although the quantitation in Table 1 relies on immunoprecipitation with specific antibodies, the analysis of [?3j-rnethionine-Iabeled polypeptides by SDS-PAGE analysis of the total conditioned medium also yielded data that were consistent with these conclusions (data not shown). Thus, the reduced expression of LA-VI11 compared with factor Vqan4 resulted from a reduced secretion efficiency.
The factor VI11 chimera harboring the.factor V B domain is jmctional. Factor VI11 activity in the conditioned medium was determined at 60 hours posttransfection. Expression of LA-VI11 yielded a slight increase in activity compared with wild-type factor VIII, proportional to the increased secretion ( twofold greater factor VllI activity in the conditioned medium compared with the wild-type factor VIII control when measured by either the Kabi Coatest factor Xa generation assay or clotting assay using factor VIII-deficient plasma ( Table 2) . Analysis of four independent transfection experiments showed the reproducibility of the transfection assay ( Table 2) . Comparison of the amount of radiolabeled polypeptide present (Table 1 ) and the amount of activity in the conditioned medium (Table 2) showed that the specific activity for the wild-type, LA-VIII, and VIIIBS factor VI11 molecules were comparable. Factor VIII, the B-domain deletion molecule LA-VIII previously characterized,32 and the VIIIBS chimera all exhibited a similar extent of activation by thrombin (Table 2 ). In addition, the timecourse of thrombin activation for wild-type factor VlIl and VIIIB5 were parallel, both showing peak activation at 1 minute (data not shown).
The susceptibility of wild-type and VIIIB5 factor VI11 to thrombin cleavage was compared by immunoprecipitation of [35S]-methionine-labeled conditioned medium and treatment of the immunoprecipitated protein with thrombin for increasing periods of time before SDS-PAGE. Comparison to the background bands observed in cells that did not receive DNA (Fig S, lanes 1 through 7) showed that wild-type factor Vlll migrated as a 200-kD polypeptide and a 80-kD light chain before thrombin digestion (Fig S, lane 8) . In contrast. the VIIIBS chimera migrated as a 330-kD polypeptide ( Fig  5, lane IS) . Upon thrombin treatment of wild-type (Fig S,   lanes 9 through 14) and of the VIIIBS chimera (Fig S, lanes  15 through 21) , the rate of appearance of the 73-kD lightchain-and SO-and 43-kD heavy-chain-derived fragments were similar. In addition, the rate of appearance and disappearance of the 90-kD heavy-chain intermediate was also similar. This finding shows that the two proteins were equally susceptible to thrombin cleavage.
The B domain of factor V is required for thrombin octivcrtion. Conditioned medium was harvested from transfected COS-l cells and factor V activity was measured in a factor V clotting assay. The activity of the VB8 and Vojnd mutants were threefold to fourfold lower compared with wild-type factor V (Table 2) . Correcting for the amount of protein secreted into the conditioned medium, the specific activity of the VsJn4 mutant was reduced sevenfold and that of VB8 was reduced 6.4-fold compared with wild-type factor V. In contrast to wild-type factor V, the VpJnJ and VB8 molecules were not activatable on thrombin treatment (Table 2 ). Both molecules also displayed significantly reduced activation by factor Xa (Table 2) . Interestingly, both VB8 and Vyjnd were activated by RVV to almost a similar degree as wild-type factor V (Table 2 ). These results show that at least a portion of VB8 and Vgdn4 molecules were folded in a manner to be activated by RVV.
The susceptibility to thrombin cleavage of wild-type factor V and the B-domain deletion mutant Vsdn4 was compared were fed fresh complete medium. After 24 hours, conditioned media samples were collected for factor Vlll and factor V activity assays as indicated and the cells were labeled with [35S1-methionine to study the synthesis and secretion as shown in Fig 3. Thrombin (Ha) and RVV activation coefficients were determined as described in Materials and Methods. The activity values are from the same transfection experiment analyzed in Fig 3. The mean activity values relative to wildtype (% w t ) and the standard deviation (SD) are presented for four independent transfection experiments with two independent preparations of DNA. Activity from mock-transfected cells was less than 1 mU/mL for factor Vlll (coatest assay) and less than 10 mUlmL for factor V (clotting assay). Abbreviation: ND, not determined here but was previously rep~rted.~'.'~ (lanes 8 through 14) or VlllB5 (lanes 15 through 21) expression vectors and after 60 hours were labeled with ["SI-methionine for 2 hours, followed by a 4-hour chase in medium containing excess unlabeled methionine. Conditioned medium was harvested and immunoprecipitated with anti-factor Vlll antibody F-8. Immunoprecipitates were resuspended and treated with thrombin (Ma; 1. by metabolically labeling transfected cells with [3sS]-methionine and analyzing the secreted protein by immunoprecipitation with a factor V-specific antibody. Incubation of the immunoprecipitated protein with increasing amounts of thrombin before reducing SDS-PAGE generated the expected cleavage products that likely represent the light chain of 74 kD, a heterogeneous heavy chain of 94 kD, and the Bdomain fragment of 150 kD characteristic of plasma-derived factor V (Fig 6, lanes 2 through 5) . In contrast, upon treatment of the Vyjf14 immunoprecipitate with increasing amounts of thrombin, there was minimal cleavage to yield the heavy chain and light chain polypeptides comigrating with wild-type thrombin-cleaved factor V (Fig 6, lanes 6  through IO) . At 100 U/mL there were still significant amounts of single-chain VYjfl4 (Fig 6, lane IO) . The factor V R domain is required for heavy and light chain association. Because the chimera VB8 was secreted primarily as a two-chain polypeptide because of intracellular proteolytic processing within the B domain of factor VIII, we investigated the association of the heavy and light chains by a coimmunoprecipitation assay. Immunoprecipitation with the factor V light-chain-specific MoAb E9 detected single-chain factor V in conditioned medium from wildtype factor V-transfected cells (Fig 7. lane 1) . Subsequent immunoprecipitation of the supernatant of the E9 precipitation with a polyclonal anti-factor V antibody identified residual amounts of immunoprecipitable wild-type factor V ( Fig  7, lane 2) . In contrast, immunoprecipitation of conditioned medium from cells transfected with VB8 detected the factor V light chain migrating at 74 kD and some single-chain polypeptide migrating at 310 kD (Fig 7, lane 3) . In addition, a heterogeneous smear migrating at approximately 120 kD was detected and may represent the factor VB8 light chain that was cleaved at the intracellular processing site within the factor VI11 B domain at residue 1313. Subsequent immunoprecipitation of the supernatant with an anti-factor V polyclonal antibody detected a significant amount of a 200-kD polypeptide, likely representing the heavy chain extending into the B domain (Fig 7, lane 4) . Thus. this analysis did not detect any association of the processed heavy chain with the processed light chain of factor VB8.
DISCUSSION
Expression of factor VI11 was 10-fold less efficient than factor V in transfected COS-1 monkey kidney cells. Because the A and C domains of factor V and VI11 are 40% identical and the B domains exhibit little sequence identity, we studied the influence of B-domain sequences on expression by analysis of B-domain4eleted and chimeric proteins. In addition, because the B domains of both cofactors are encoded by single large exons it is likely they evolved by divergence from an ancestral exon; thus, it was of interest to evaluate whether they exhibit similar properties when contained in chimeric molecules. In this report, we have characterized the effect of the B domain on expression and functional properties of the secreted factors V and VIII.
Analysis of the levels of mRNA and secreted protein obtained from expression of wild-type factor VI11 and factor V in transiently transfected COS-l cells provided insights into factors responsible for the inefficient expression of factor VIII. The steady-state level of factor V mRNA was approximately twofold greater than factor VI11 mRNA. Analysis of primary translation products indicated that both mRNAs were translated with equal efficiency; however, the factor V translation product was fivefold more efficiently secreted into the conditioned medium. The increased secretion efficiency of factor V compared with factor VI11 was also observed in Chinese hamster ovary cells (our unpublished data), indicating that the differences in secretion were not unique to the COS-1 cell transfection system. The difference in secretion efficiency indicates that these two homologous proteins exhibit different requirements for transport through the secretory pathway. Whereas newly synthesized factor VI11 significantly binds the protein chaperone BiP within the lumen of the endoplasmic recent studies have shown that factor V expressed in C H 0 cells does not detectably bind BiP."
In addition, depletion of intracellular ATP inhibited factor VI11 secretion."" with no effect on factor V secretion."
Analysis of the expression of chimeric cDNAs having the B domains exchanged indicated that the levels of mRNA expressed were intermediate to those of wild-type factor V and factor VIII, suggesting that sequences within the B domain were partially responsible for the difference in mRNA levels expressed for factors V and VIII. Deletion of the B domain within either the factor V or factor VI11 cDNA increased mRNA expression 3.4-and 17-fold, respectively. This finding shows that in this expression system the Bdomain sequences are detrimental for factor V mRNA expression and. to a greater extent. for factor Vlll mRNA expression. For the wild-type and mutant factor V and factor VI11 molecules, the steady-state levels of mRNA were proportional to the levels of primary translation products, indicating that there were no significant differences in translational efficiency for the different mRNAs. The factor VI11 chimera containing the factor V B domain was secreted with a similar efficiency to wild-type factor VIII. Similarly, the factor V chimera containing the factor VI11 B domain was secreted with a similar efficiency to wild-type factor V. Thus, this analysis did not detect any differences in secretion efficiency that could be attributed to unique properties of the B domains of factors V and/or VIII. In addition, deletion of the B domain in factor V increased the amount of secreted protein proportional to the increase in mRNA, showing that wild-type and B-domain-deleted factor V are secreted with equally high efficiency. In contrast, the amount of secreted protein for the B-domain-deleted factor VI11 did not increase proportionally to the increase in mRNA. These results suggest that regions outside the B domain are responsible For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From for BiP interaction and significantly reduce the secretion efficiency of factor VIII. We are presently constructing additional chimeras to identify regions responsible for the reduced secretion efficiency of factor VIII.
Factor V is secreted as a single-chain molecule, whereas factor VIII is proteolytically processed intracellularly at two sites within the B domain to yield a heterodimer.4' A factor VI11 chimera that had the factor V B domain was secreted as a single-chain polypeptide at a twofold greater level than wild-type factor VIII. The chimeric protein had a specific activity similar to wild-type factor VIII. In addition, there was no detectable difference in thrombin cleavage and activation, Previous studies on B-domain-deleted factor VI11 molecules indicated that removal of the B domain altered the sensitivity to thrombin activation and/or ~l e a v a g e .~~,~' .~~ For example, factor VI11 B-domain deletion molecules exhibited either increased sensitivity to thrombin activation?9 increased sensitivity to thrombin cleavage of the light chain,32 or an increased thrombin a~tivation.~' The results reported here show that substitution of the factor V B domain into factor VI11 restored the wild-type pattern of thrombin activation. We suggest that the context of the thrombin cleavage site is more accurately presented in the hybrid protein than in the B domain deletion molecules. In addition, because there is little homology between the factor V and factor VI11 B domains, these results suggest that there is no unique primary amino acid sequence requirement for the B domain and that B-domain sequences in factor VI11 may simply function to separate the heavy and light chains before activation.
In contrast to factor VIII, several observations reported here support that the B domain of factor V is required for factor V structure and activation. First, replacement of the factor VI11 B domain for the factor V B domain resulted in a molecule with a 6.5-fold reduced specific activity that was resistant to thrombin activation. The chimeric protein was secreted as two forms comprising a single-chain polypeptide and cleaved and dissociated heavy-and light-chain polypeptides. The reduced specific activity of the chimera was likely caused by dissociation of the heavy and light chains. The secretion of dissociated chains suggests that a further requirement for the B domain of factor V may be to facilitate protein folding in such a way as to promote heavy-and lightchain association. However, it is not possible to rule out that the heterologous factor VI11 B domain affected protein folding to prevent chain association. The single-chain polypeptide of the factor V chimera was sensitive to thrombin cleavage, but did not display thrombin activation of procoagulant activity. In addition, the factor V chimera displayed significantly reduced activation by factor Xa. In a detailed study of the kinetics of factor Xa and thrombin activation of human factor V it was concluded that factor Xa cleaves initially after residue I018 and then after 709, whereas thrombin cleaves initially after residue 709 and then after 1018.25 The absence of the cleavage site at 1018 or alteration in the conformation of the cleavage site at 709 within the chimeric protein may account for the loss of activation by these proteases. However, RVV treatment increased the activity of the chimeric protein to a fold similar to that of wild-type factor V, suggesting that a portion of the chimeric molecules were folded in a functional manner. Because the protease responsible for factor V activation in RVV cleaves once after residue 1545," these results suggest that a single cleavage at 1545 can activate the chimeric protein.
Deletion of the factor V B domain from residue 710 to 1545 resulted in a molecule that was very efficiently expressed but had a sevenfold reduced specific activity compared with wild-type factor V and was not effectively cleaved by thrombin to an active form. However, this molecule was activated by RVV, showing that a portion of the secreted molecules were folded in a manner that were activatable and functional after RVV treatment, similar to the factor V B-domain chimeric molecule. Kane et described a factor V B-domain deletion molecule that retained susceptibility to thrombin cleavage and was activatable by RVV. 33 The mutant described by Kane et a133 contained an additional 168 amino acids within the B domain that were lacking in the mutant described here. Because these extra amino acids include a region rich in acidic amino acids with three potential sites of tyrosine sulfation at residues 1494, 1510, and 1515,49 we propose that this region is important for thrombin interaction for cleavage at residue 1545, similar to that observed for the carboxy-terminal acidic amino acid-rich region of hirudin.50 Consistent with this hypothesis, nonsulfated factor V exhibits delayed thrombin cleavage and activation, whereas factor Xa cleavage and activation were not affe~ted.~' The loss of activity for the factor V B-domain deletion molecule that juxtaposes two thrombin cleavages sites at 709 and 1545 are in contrast to observations with the factor VI11 B-domain deletions that juxtapose the thrombin cleavage sites at 740 and 1689 and yield functional and thrombin activatable molecule^.*^*^^^^^ The results described here show that sequences within the B domain of factor V are required for proper thrombin-and, to a lesser extent, factor Xa-mediated activation of factor V. In contrast, RVV did not exhibit any requirement for sequences within the B domain for factor V activation. This finding suggests that RVV activation does not require the acidic region within the factor V B domain (residues 1493-1545). Although there should be caution from drawing conclusions from mutant proteins, the results from analysis of the factor V B-domain deletion molecule are consistent with those of the factor V/ factor VI11 B-domain chimeric molecule and both suggest that the factor V B domain is required for thrombin activation but not for RVV-mediated activation.
